Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL

Blood

Volumn 111, Issue 5, 2008, Pages 2797-2805

  Liu, Feng Ting ^a   Agrawal, Samir G ^a   Gribben, John G ^b   Ye, Hongtao ^c   Du, Ming Qing ^c   Newland, Adrian C ^a   Jia, Li ^a,d  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BID; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; POLYUBIQUITIN; PYRAZINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL CULTURE; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROTEIN PROCESSING; THERMODYNAMICS; UBIQUITINATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; BCL-2-ASSOCIATED X PROTEIN; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BORONIC ACIDS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOCHONDRIA; POLYUBIQUITIN; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRAZINES; THERMODYNAMICS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; UBIQUITINATION;

EID: 41949136647     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-08-110445     Document Type: Article

References (55)

1. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA. 2000;97:3850-3855.
2. Miyashita T, Kitada S, Krajewski S, et al. Overex-pression of the Bcl-2 protein increases the half-life of p21Bax. J Biol Chem. 1995;270:26049-26052.
3. McConkey DJ, Chandra J, Wright S, et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol. 1996;156:2624-2630.
4. Chang YC, Lee YS, Tejima T, et al. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ. 1998;9:79-84.
5. Fecker LF, Geilen CC, Tchernev G, et al. Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol. 2006;126:1366-1371.
6. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillo-mavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63:1129-1136.
7. Breitschopf K, Zeiher AM, Dimmeler S. Ubiquitin-mediated degradation of the proapoptotic active form of bid. Afunctional consequence on apopto-sis induction. J Biol Chem. 2000;275:21648-21652.
8. Lotan R, Rotem A, Gonen H, et al. Regulation of the proapoptotic ARTS protein by ubiquitin-medi-ated degradation. J Biol Chem. 2005;280:25802-25810.
9. Perez-Galan P, Roue G, Villamor N, et al. The proteasome inhibitor bortezomib induces apopto-sis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006;107:257-264.
10. Kuroda J, Puthalakath H, Cragg MS, et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA. 2006;103:14907- 14912.
11. Aguilar-Santelises M, Rottenberg ME, Lewin N, et al. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer. 1996;69:114-119.
12. Chresta CM, Masters JR, Hickman JA. Hypersen-sitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res. 1996;56:1834-1841.
13. Schmitt E, Steyaert A, Cimoli G, et al. Bax-alpha promotes apoptosis induced by cancer chemotherapy and accelerates the activation of caspase 3-like cysteine proteases in p53 double mutant B lymphoma Namalwa cells. Cell Death Differ. 1998;5:506-516.
14. Nishii K, Gibbons DL, Titley I, et al. Regulation of the apoptotic response to radiation damage in B cell development. Cell Death Differ. 1998;5:77-86.
15. Jia L, Patwari Y, Srinivasula SM, et al. Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis. Oncogene. 2001;20:4817-4826.
16. Liu FT, Goff LK, Hao JH, et al. Increase in the ratio of mitochondrial Bax/Bcl-XL induces Bax activation in human leukemic K562 cell line. Apopto-sis. 2004;9:377-384.
17. Dewson G, Snowden R. Almond J, et al. Confor-mational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells. Oncogene. 2003;22:2643-2654.
18. Chitambar CR, Wereley JP, Matsuyama S. Gallium-induced cell death in lymphoma: role of transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of proteasome inhibition. Mol Cancer Ther. 2006;5:2834-2843.
19. Sutheesophon K, Kobayashi Y, Takatoku MA, et al. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. Acta Haematol. 2006;115:78-90.
20. Pigneux A, Mahon FX, Moreau-Gaudry F, et al. Proteasome inhibition specifically sensitizes leu-kemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteins. Cancer Biol Ther. 2007;6:[Epub ahead of print]
21. MacFarlane M, Harper N, Snowden RT, et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene. 2002;21:6809-6818.
22. Inoue S, Mai A, Dyer MJ, et al. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2006;66:6785-6792.
23. Hao XS, Hao JH, Liu FT, et al. Potential mechanisms of leukemia cell resistance to TRAIL-induced apoptosis. Apoptosis. 2003;8:601-607.
24. Schwartz R, Davidson T. Pharmacology, pharma-cokinetics, and practical applications of bortezomib. Oncology (Williston Park). 2004;18(14 Suppl 11):14-21.
25. Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Bio-chem. 2001;82:110-122.
26. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639-16647.
27. Lashinger LM, Zhu K, Williams SA, et al. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res. 2005;65:4902-4908.
28. Qin JZ, Ziffra J, Stennett L, et al. Proteasome in-hibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 2005;65:6282-6293.
29. Kabore AF, Sun J, Hu X, et al. The TRAIL apopto-tic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis. 2006;11:1175-1193.
30. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apopto-sis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood. 2001;98:795-804.
31. Sayers TJ, Brooks AD, Koh CY, et al. The protea-some inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood. 2003;102:303-310.
32. Johnson TR, Stone K, Nikrad M, et al. The pro-teasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene. 2003;22:4953-4963.
33. Brooks AD, Ramirez T, Toh U, et al. The protea-some inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis. Ann N Y Acad Sci. 2005;1059:160-167.
34. Nikrad M, Johnson T, Puthalalath H, et al. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAILvia BH3-only proteins Bik and Bim. Mol Cancer Ther. 2005;4:443-449.
35. Lundqvist A, Abrams SI, Schrump DS, et al. Bort-ezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 2006;66:7317-7325.
36. Beckwith M, Longo DL, O'Connell CD, et al. Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines. J Natl Cancer Inst. 1990;82:501-509.
37. Kluin-Nelemans HC, Limpens J, Meerabux J, et al. A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14;18)(q32;q21). Leukemia. 1991;5:221-224.
38. Strauss SJ, Higginbottom K, Juliger S. The pro-teasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res. 2007;67:2783-2790.
39. Jia L, Macey MG, Yin Y, et al. Subcellular distribution and redistribution of Bcl-2 family proteins in human leukemia cells undergoing apoptosis. Blood. 1999;93:2353-2359.
40. Liu FT, Newland AC, Jia L. Bax conformational change is a crucial step for PUMA-mediated apo-ptosis in human leukemia. Biochem Biophys Res Commun. 2003;310:956-962.
41. Rudner J, Jendrossek V, Lauber K, et al. Type I and type II reactions in TRAIL-induced apoptosis -results from dose-response studies. Oncogene. 2005;24:130-140.
42. Jia L, Patwari Y, Kelsey SM, et al. Trail-induced apoptosis in Type I leukemic cells is not enhanced by overexpression of Bax. Biochem Bio-phys Res Commun. 2001;283:1037-1045.
43. Dohmen J. Chapter 12: Primary destruction signals. Proteasomes: The world of regulatoryprote-olysis. Wolfgang Hilt and Dieter H. Wolf. 2000;186-203.
44. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 1998;17:7151-7160.
45. Upton JP, Valentijn AJ, Zhang L, et al. The N-terminal conformation of Bax regulates cell commitment to apoptosis. Cell Death Differ. 2007;14:932-942.
46. Hsu YT, Youle RJ. Bax in murine thymus is a soluble monomeric protein that displays differential detergent-induced conformations. J Biol Chem. 1998;273:10777-10783.
47. Willis SN, Fletcher JI, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science. 2007;315:85685-85689.
48. Clohessy JG, Zhuang J, de Boer J, et al. Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J Biol Chem. 2006;281:5750-5759.
49. Hao JH, Yu M, Liu FT, et al. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. Cancer Res. 2004;64:3607-3616.
50. Fandy TE, Srivastava RK. Trichostatin Asensi-tizes TRAIL-resistant myeloma cells by down-regulation of the antiapoptotic Bcl-2 proteins. Cancer Chemother Pharmacol. 2006;58:471-477.
51. Bosanquet AG, Sturm I, Wieder T, et al. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia. Leukemia. 2002;16:1035-1044.
52. Saxena A, Viswanathan S, Moshynska O, et al. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol. 2004;75:22-33.
53. Pahler JC, Ruiz S, Niemer I, et al. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res. 2003;9:4570-4577.
54. Kelley TW, Alkan S, Srkalovic G, et al. Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Leuk Res. 2004;28:845-850.
55. Smolewski P, Duechler M, Linke A, et al. Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells. Leuk Res. 2006;30:1521-1529.